A61P 31/22
For herpes viruses
Official title: for herpes viruses
A61P31/22 (For herpes viruses) appears on 3,502 US grants and 5,256 published applications in this corpus.
Search patents in A61P- Granted patents
- 3,502
- Published applications
- 5,256
- Assignees
- 2,000
- Inventors
- 9,054
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 4 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 5 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 4 | 0 |
| 1992 | 2 | 0 |
| 1993 | 11 | 0 |
| 1994 | 12 | 0 |
| 1995 | 21 | 0 |
| 1996 | 23 | 0 |
| 1997 | 27 | 0 |
| 1998 | 55 | 0 |
| 1999 | 54 | 0 |
| 2000 | 58 | 0 |
| 2001 | 82 | 20 |
| 2002 | 89 | 121 |
| 2003 | 84 | 190 |
| 2004 | 69 | 214 |
| 2005 | 85 | 233 |
| 2006 | 85 | 191 |
| 2007 | 90 | 239 |
| 2008 | 94 | 219 |
| 2009 | 111 | 294 |
| 2010 | 140 | 377 |
| 2011 | 157 | 316 |
| 2012 | 212 | 357 |
| 2013 | 181 | 249 |
| 2014 | 239 | 225 |
| 2015 | 170 | 227 |
| 2016 | 172 | 222 |
| 2017 | 175 | 195 |
| 2018 | 157 | 189 |
| 2019 | 165 | 203 |
| 2020 | 139 | 206 |
| 2021 | 132 | 161 |
| 2022 | 100 | 117 |
| 2023 | 72 | 161 |
| 2024 | 65 | 140 |
| 2025 | 85 | 112 |
| 2026 | 54 | 78 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses6 Oct 2026US 12,753,187 B2Merck Sharp & Dohme Corp.
- Treatment of herpes zoster with topical tetracaine22 Sep 2026US 12,740,960 B2Pagari Life Science Corp
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Vaccines, vaccine priming, and antigen dose sparing22 Sep 2026US 12,741,022 B2Adjuvance Technologies, Inc.
- Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-y1]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use22 Sep 2026US 12,741,943 B2AIC246 AG & Co. KG
- Oral pharmaceutical compositions1 Oct 2026US 2026/0294910 A1Assembly Biosciences, Inc.
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- Hdac inhibitors for use with nk cell based therapies24 Sep 2026US 2026/0284060 A9NantKwest, Inc.
- Histone deacetylase inhibitors for use in immunotherapy24 Sep 2026US 2026/0284061 A9Viracta Subsidiary, Inc.
- Indolinyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy10 Sep 2026US 2026/0263434 A1
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Sustained release drug delivery devices360US 5,902,598 AControl Delivery Systems, Inc. · 1999
- Immunomodulatory oligonucleotides335US 6,194,388 B1Coley Pharmaceutical Group, Inc. · 2001
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009